GlaxoSmithKline: Phase III RUBY Clinical Trial Demonstrates Potential of Jemperli Plus Chemotherapy to Redefine the Treatment of Primary Advanced or Recurrent Endometrial Cancer Versus Chemotherapy Alone
March 28, 2023
March 28, 2023
LONDON, England, March 28 (TNSres) -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on March 27, 2023:
GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent . . .
GSK plc (LSE/NYSE: GSK) today announced interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent . . .